Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001611024-25-000004·Allogene Therapeutics, Inc.
Schedule 13G ownership disclosure
Allogene Therapeutics Inc
Common Stock · CUSIP: 019770106
Event date: 2025-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- David D. Chang, M.D., Ph.D.
Shares: 11,234,918.00 · Class: 4.9%
- Chang 2006 Family Trust
Shares: 1,201,108.00 · Class: 0.5%
- JEC 2019 Trust
Shares: 856,044.00 · Class: 0.4%
- RTC 2019 Trust
Shares: 856,044.00 · Class: 0.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001611024-25-000004
- Form type
- SCHEDULE 13G/A
- Filer
- Allogene Therapeutics, Inc.
- CIK
- CIK 1737287
- Filed
- Nov 12, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership